In the United States, radioembolization is indicated for the main treatment for liver cancer or as additional treatment to surgery or transplantation in patients with liver cancer who cannot be treated with surgery. Radioembolization is approved by the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE). HDE approvals are based on demonstrated safety and probable benefit. However, effectiveness of the indication for use has not been established. The treatment is a 2-step process whereby a preliminary procedure must be performed to determine whether a patient is eligible to be treated with radioembolization.
YOU CAN LOWER YOUR RISK FOR PAD
Timely detection and treatment of PAD can improve the quality of your life; help you keep your independence and mobility; and reduce your risk of heart attack, stroke, leg amputation, and even death.